American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Compugen Ltd

CGEN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

CGEN historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of CGEN by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Sale $15,001 - $50,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 N/A
CGEN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CGEN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CGEN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in CGEN holdings by institutional investors

Insider Trading

Quarterly net insider trading by CGEN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Revolving Door

Former government officials who have lobbied for CGEN

Quiver Logo

No former government officials on record as having lobbied for CGEN

Revolving Door Dashboard
Corporate Lobbying

CGEN Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

CGEN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CGEN Income Statement
CGEN Balance Sheet
CGEN Cash Flow
U.S. Patents

New CGEN patent grants

  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Feb. 24, 2026
  • Patent Title: Anti-pvrig antibodies and methods of use May. 27, 2025
  • Patent Title: Triple combination antibody therapies Nov. 26, 2024
  • Patent Title: Anti-pvrig antibodies and methods of use Oct. 24, 2023
  • Patent Title: Pvrig polypeptides and methods of treatment Oct. 24, 2023
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Jul. 18, 2023
  • Patent Title: Anti-pvrig antibodies and methods of use Apr. 11, 2023
  • Patent Title: Triple combination antibody therapies Jan. 18, 2022
  • Patent Title: Anti-pvrig antibodies and methods of use Jan. 11, 2022
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Aug. 25, 2020
  • Patent Title: Pvrig polypeptides and methods of treatment Feb. 04, 2020
  • Patent Title: Anti-pvrig antibodies and methods of use Jul. 16, 2019
  • Patent Title: Anti-pvrig antibodies and methods of use Mar. 12, 2019
  • Patent Title: Anti-tigit anibodies, anti-pvrig antibodies and combinations thereof Feb. 26, 2019
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Nov. 13, 2018
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Oct. 16, 2018
  • Patent Title: Anti-pvrig antibodies and methods of use Jul. 25, 2017
  • Patent Title: C10rf32 antibodies, and uses thereof for treatment of cancer Apr. 11, 2017
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jan. 31, 2017
  • Patent Title: Heparanase splice variant Aug. 30, 2016
  • Patent Title: Polypeptides and uses thereof for treatment of autoimmune disorders and infection Aug. 30, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer Aug. 09, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jun. 28, 2016
  • Patent Title: Soluble vegfr-1 variants for diagnosis of preeclampsia May. 24, 2016
  • Patent Title: Angiopoietin derived peptides Feb. 09, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Aug. 18, 2015
  • Patent Title: Compositions and methods for treatment of drug resistant multiple myeloma Apr. 07, 2015
  • Patent Title: Bioactive peptides and methods of using same Mar. 24, 2015
  • Patent Title: Method of treating an ischemia-reperfusion injury-related disorder by administering gpcr ligands Sep. 09, 2014
  • Patent Title: Clusterin derived peptide Nov. 05, 2013
  • Patent Title: Angiopoietin derived peptides Sep. 10, 2013
  • Patent Title: Gp96 derived peptides Aug. 20, 2013
  • Patent Title: Bioactive peptides and methods of using same Jul. 23, 2013
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Apr. 09, 2013
  • Patent Title: Peptide ligands for g-protein coupled receptors Jan. 08, 2013
  • Patent Title: Polynucleotides encoding polypeptides and methods using same May. 10, 2011
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer Mar. 15, 2011
  • Patent Title: Peptides which bind to g protein-coupled receptors Feb. 08, 2011
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis Nov. 30, 2010
  • Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Jul. 20, 2010
  • Patent Title: Human thrombospondin polypeptide Jun. 29, 2010
  • Patent Title: Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof Jun. 22, 2010
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease May. 11, 2010
  • Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Mar. 16, 2010
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Feb. 23, 2010
  • Patent Title: Variants of human glycoprotein hormone alpha chain: compositions and uses thereof Feb. 02, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to CGEN from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
CGEN News

Recent insights relating to CGEN

CNBC Recommendations

Recent picks made for CGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CGEN

CGEN Analyst Ratings

CGEN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CGEN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CGEN stock a Buy, Sell, or Hold?

  • What is the price target for $CGEN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CGEN Top Shareholders
Shareholder
Shares Held
CGEN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CGEN stock?

  • Who owns the most shares of $CGEN stock?

  • What funds own $CGEN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CGEN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CGEN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About CGEN

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Compugen Ltd (CGEN) Historical Stock Prices

Compugen Ltd (CGEN) closed at $2.38 on September 25, 2026. Over the past year its adjusted close ranged from $1.38 to $3.10. Daily prices go back to January 2, 2014, 3,202 trading days in all.

  • 1 month-16.20%
  • 3 months+13.88%
  • Year to date+55.56%
  • 1 year+72.46%
  • 3 years+147.07%
  • 5 years-61.74%
  • Max-73.44%
See every congressional and insider trade on the CGEN price chart

Quiver Premium charts CGEN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 25, 2026 2.40 2.42 2.35 2.38 2.38 77,756
Sep 24, 2026 2.34 2.38 2.33 2.37 2.37 111,364
Sep 23, 2026 2.45 2.47 2.31 2.34 2.34 288,332
Sep 22, 2026 2.46 2.50 2.40 2.49 2.49 230,978
Sep 21, 2026 2.45 2.50 2.42 2.44 2.44 217,393
Sep 18, 2026 2.47 2.49 2.45 2.49 2.49 128,001
Sep 17, 2026 2.42 2.47 2.42 2.46 2.46 122,757
Sep 16, 2026 2.41 2.47 2.40 2.41 2.41 117,641
Sep 15, 2026 2.49 2.49 2.37 2.41 2.41 330,761
Sep 14, 2026 2.42 2.54 2.42 2.48 2.48 144,471
Sep 11, 2026 2.47 2.50 2.43 2.47 2.47 162,163
Sep 10, 2026 2.48 2.51 2.44 2.46 2.46 206,983
Sep 9, 2026 2.55 2.55 2.46 2.48 2.48 293,782
Sep 8, 2026 2.55 2.62 2.55 2.56 2.56 192,901
Sep 4, 2026 2.54 2.61 2.54 2.59 2.59 199,695
Sep 3, 2026 2.64 2.66 2.54 2.56 2.56 163,617
Sep 2, 2026 2.56 2.63 2.56 2.63 2.63 127,918
Sep 1, 2026 2.56 2.60 2.53 2.59 2.59 168,925
Aug 31, 2026 2.63 2.63 2.52 2.56 2.56 175,117
Aug 28, 2026 2.72 2.72 2.58 2.60 2.60 228,794
Aug 27, 2026 2.86 2.86 2.72 2.76 2.76 301,266
Aug 26, 2026 2.83 2.94 2.80 2.84 2.84 667,034
Aug 25, 2026 2.60 2.91 2.59 2.87 2.87 799,789
Aug 24, 2026 2.58 2.60 2.49 2.59 2.59 218,360
Aug 21, 2026 2.64 2.77 2.61 2.62 2.62 447,161
Aug 20, 2026 2.54 2.68 2.47 2.65 2.65 993,918
Aug 19, 2026 2.36 2.48 2.36 2.44 2.44 212,891
Aug 18, 2026 2.33 2.39 2.30 2.38 2.38 98,185
Aug 17, 2026 2.38 2.40 2.33 2.35 2.35 201,486
Aug 14, 2026 2.40 2.43 2.35 2.41 2.41 191,226
Aug 13, 2026 2.50 2.50 2.39 2.41 2.41 280,003
Aug 12, 2026 2.44 2.50 2.42 2.50 2.50 447,014
Aug 11, 2026 2.36 2.46 2.34 2.40 2.40 297,200
Aug 10, 2026 2.35 2.41 2.31 2.34 2.34 231,428
Aug 7, 2026 2.32 2.43 2.31 2.41 2.41 276,177
Aug 6, 2026 2.31 2.36 2.28 2.30 2.30 207,067
Aug 5, 2026 2.35 2.37 2.26 2.28 2.28 238,879
Aug 4, 2026 2.36 2.44 2.33 2.38 2.38 345,347
Aug 3, 2026 2.34 2.38 2.17 2.38 2.38 592,869
Jul 31, 2026 2.32 2.38 2.25 2.35 2.35 350,225
Jul 30, 2026 2.26 2.35 2.24 2.33 2.33 165,032
Jul 29, 2026 2.28 2.31 2.22 2.24 2.24 198,382
Jul 28, 2026 2.38 2.38 2.24 2.26 2.26 179,048
Jul 27, 2026 2.34 2.38 2.28 2.38 2.38 103,763
Jul 24, 2026 2.38 2.38 2.26 2.28 2.28 200,167
Jul 23, 2026 2.39 2.40 2.33 2.34 2.34 174,536
Jul 22, 2026 2.45 2.51 2.39 2.42 2.42 184,414
Jul 21, 2026 2.35 2.52 2.34 2.49 2.49 255,327
Jul 20, 2026 2.36 2.38 2.32 2.34 2.34 262,650
Jul 17, 2026 2.30 2.38 2.27 2.37 2.37 154,849
Jul 16, 2026 2.43 2.43 2.29 2.33 2.33 398,324
Jul 15, 2026 2.39 2.43 2.33 2.36 2.36 207,141
Jul 14, 2026 2.31 2.32 2.22 2.30 2.30 142,019
Jul 13, 2026 2.36 2.38 2.29 2.30 2.30 234,688
Jul 10, 2026 2.48 2.48 2.37 2.39 2.39 158,767
Jul 9, 2026 2.47 2.56 2.44 2.47 2.47 427,749
Jul 8, 2026 2.39 2.44 2.34 2.41 2.41 370,673
Jul 7, 2026 2.34 2.41 2.31 2.39 2.39 220,946
Jul 6, 2026 2.32 2.38 2.29 2.36 2.36 331,204
Jul 2, 2026 2.12 2.29 2.12 2.28 2.28 495,002
Jul 1, 2026 2.17 2.18 2.10 2.13 2.13 173,439
Jun 30, 2026 2.15 2.19 2.12 2.14 2.14 286,230
Jun 29, 2026 2.09 2.17 2.09 2.16 2.16 257,138
Jun 26, 2026 2.03 2.10 2.01 2.09 2.09 293,512
Jun 25, 2026 2.05 2.06 2.02 2.02 2.02 236,051
Jun 24, 2026 2.03 2.04 1.99 2.01 2.01 161,956
Jun 23, 2026 2.03 2.10 2.00 2.02 2.02 268,881
Jun 22, 2026 2.02 2.10 2.02 2.07 2.07 235,134
Jun 18, 2026 2.05 2.08 1.96 2.01 2.01 503,834
Jun 17, 2026 2.01 2.07 1.98 1.99 1.99 275,729
Jun 16, 2026 2.02 2.04 1.97 2.03 2.03 346,043
Jun 15, 2026 2.04 2.09 2.00 2.02 2.02 288,554
Jun 12, 2026 2.05 2.12 2.00 2.04 2.04 206,978
Jun 11, 2026 1.98 2.06 1.96 2.04 2.04 359,262
Jun 10, 2026 2.02 2.04 1.95 1.96 1.96 352,744
Jun 9, 2026 2.09 2.09 1.95 2.02 2.02 462,765
Jun 8, 2026 2.12 2.14 2.02 2.04 2.04 458,936
Jun 5, 2026 2.19 2.20 2.07 2.10 2.10 242,581
Jun 4, 2026 2.20 2.26 2.20 2.22 2.22 574,906
Jun 3, 2026 2.24 2.24 2.12 2.19 2.19 807,881
Jun 2, 2026 2.43 2.43 2.23 2.26 2.26 1,117,496
Jun 1, 2026 2.61 2.61 2.43 2.46 2.46 738,369
May 29, 2026 2.77 2.77 2.63 2.63 2.63 373,865
May 28, 2026 2.80 2.83 2.73 2.78 2.78 545,649
May 27, 2026 2.72 2.78 2.65 2.76 2.76 366,539
May 26, 2026 2.80 2.80 2.65 2.65 2.65 418,078
May 22, 2026 2.64 2.92 2.64 2.80 2.80 580,142
May 21, 2026 2.69 2.71 2.54 2.61 2.61 541,388
May 20, 2026 2.73 2.78 2.70 2.71 2.71 265,467
May 19, 2026 2.75 2.90 2.57 2.73 2.73 956,048
May 18, 2026 2.84 3.02 2.69 2.86 2.86 1,704,134
May 15, 2026 2.95 2.95 2.72 2.75 2.75 834,219
May 14, 2026 2.89 3.05 2.82 3.03 3.03 772,907
May 13, 2026 2.82 2.85 2.81 2.85 2.85 131,937
May 12, 2026 2.79 2.85 2.70 2.83 2.83 323,922
May 11, 2026 2.84 2.98 2.79 2.87 2.87 444,195
May 8, 2026 2.90 2.95 2.83 2.90 2.90 337,767
May 7, 2026 2.76 2.93 2.76 2.86 2.86 411,006
May 6, 2026 2.75 2.79 2.69 2.76 2.76 405,584
May 5, 2026 2.68 2.84 2.68 2.72 2.72 452,594
May 4, 2026 2.68 2.73 2.60 2.64 2.64 476,175
May 1, 2026 2.66 2.77 2.66 2.71 2.71 426,383
Apr 30, 2026 2.62 2.68 2.56 2.66 2.66 345,234
Apr 29, 2026 2.71 2.76 2.54 2.60 2.60 727,739
Apr 28, 2026 2.89 2.90 2.67 2.73 2.73 817,802
Apr 27, 2026 3.08 3.13 2.88 2.92 2.92 946,842
Apr 24, 2026 3.00 3.23 2.95 3.10 3.10 1,248,437
Apr 23, 2026 2.81 2.99 2.79 2.92 2.92 582,047
Apr 22, 2026 2.87 2.90 2.80 2.83 2.83 302,962
Apr 21, 2026 2.91 2.91 2.77 2.84 2.84 278,404
Apr 20, 2026 2.82 2.90 2.81 2.88 2.88 274,647
Apr 17, 2026 2.91 2.92 2.77 2.82 2.82 660,369
Apr 16, 2026 2.84 2.91 2.82 2.89 2.89 480,046
Apr 15, 2026 2.87 2.94 2.72 2.89 2.89 672,745
Apr 14, 2026 2.80 2.94 2.77 2.88 2.88 885,119
Apr 13, 2026 2.52 2.78 2.50 2.76 2.76 678,346
Apr 10, 2026 2.48 2.65 2.41 2.58 2.58 765,695
Apr 9, 2026 2.31 2.49 2.28 2.48 2.48 437,019
Apr 8, 2026 2.42 2.45 2.27 2.29 2.29 294,588
Apr 7, 2026 2.19 2.35 2.19 2.32 2.32 486,994
Apr 6, 2026 2.18 2.30 2.17 2.18 2.18 379,564
Apr 2, 2026 2.20 2.28 2.19 2.26 2.26 205,711
Apr 1, 2026 2.13 2.28 2.13 2.20 2.20 217,168
Mar 31, 2026 1.99 2.15 1.99 2.13 2.13 266,749
Mar 30, 2026 2.03 2.06 1.98 1.99 1.99 189,808
Mar 27, 2026 2.04 2.09 2.01 2.04 2.04 141,847
Mar 26, 2026 2.02 2.12 2.02 2.06 2.06 128,343
Mar 25, 2026 2.09 2.17 2.06 2.06 2.06 120,692
Mar 24, 2026 2.07 2.12 2.05 2.07 2.07 137,360
Mar 23, 2026 2.13 2.15 2.07 2.09 2.09 230,144
Mar 20, 2026 2.11 2.17 2.08 2.09 2.09 194,164
Mar 19, 2026 2.13 2.15 2.09 2.11 2.11 184,627
Mar 18, 2026 2.28 2.28 2.13 2.17 2.17 265,333
Mar 17, 2026 2.25 2.33 2.25 2.27 2.27 181,852
Mar 16, 2026 2.29 2.33 2.21 2.27 2.27 398,916
Mar 13, 2026 2.22 2.35 2.22 2.24 2.24 307,702
Mar 12, 2026 2.21 2.26 2.16 2.21 2.21 301,879
Mar 11, 2026 2.19 2.31 2.19 2.28 2.28 429,158
Mar 10, 2026 2.14 2.24 2.10 2.24 2.24 372,165
Mar 9, 2026 2.05 2.16 2.03 2.15 2.15 234,815
Mar 6, 2026 2.00 2.16 2.00 2.08 2.08 190,678
Mar 5, 2026 2.13 2.13 2.00 2.05 2.05 206,396
Mar 4, 2026 2.02 2.18 2.02 2.14 2.14 266,633
Mar 3, 2026 2.23 2.31 1.98 2.00 2.00 524,128
Mar 2, 2026 1.90 2.29 1.89 2.25 2.25 2,116,678
Feb 27, 2026 1.78 1.90 1.74 1.81 1.81 334,238
Feb 26, 2026 1.80 1.80 1.72 1.79 1.79 97,768
Feb 25, 2026 1.77 1.79 1.74 1.76 1.76 103,270
Feb 24, 2026 1.71 1.81 1.69 1.77 1.77 202,394
Feb 23, 2026 1.74 1.75 1.67 1.71 1.71 160,807
Feb 20, 2026 1.76 1.81 1.74 1.74 1.74 150,356
Feb 19, 2026 1.68 1.80 1.66 1.79 1.79 238,976
Feb 18, 2026 1.68 1.73 1.66 1.70 1.70 185,669
Feb 17, 2026 1.65 1.71 1.63 1.68 1.68 132,886
Feb 13, 2026 1.66 1.70 1.64 1.65 1.65 129,723
Feb 12, 2026 1.70 1.71 1.63 1.67 1.67 124,184
Feb 11, 2026 1.77 1.78 1.70 1.71 1.71 183,552
Feb 10, 2026 1.73 1.82 1.73 1.76 1.76 329,592
Feb 9, 2026 1.70 1.72 1.66 1.71 1.71 179,418
Feb 6, 2026 1.61 1.71 1.60 1.67 1.67 296,292
Feb 5, 2026 1.74 1.76 1.58 1.59 1.59 450,980
Feb 4, 2026 1.80 1.81 1.71 1.74 1.74 267,723
Feb 3, 2026 1.82 1.85 1.78 1.82 1.82 204,815
Feb 2, 2026 1.82 1.87 1.81 1.81 1.81 180,761
Jan 30, 2026 1.93 1.93 1.83 1.84 1.84 214,995
Jan 29, 2026 1.96 1.98 1.91 1.93 1.93 170,260
Jan 28, 2026 2.02 2.03 1.94 1.95 1.95 291,810
Jan 27, 2026 2.08 2.08 1.98 2.02 2.02 241,759
Jan 26, 2026 2.06 2.07 2.02 2.03 2.03 131,389
Jan 23, 2026 2.17 2.18 2.08 2.09 2.09 154,297
Jan 22, 2026 2.12 2.21 2.12 2.14 2.14 212,489
Jan 21, 2026 2.17 2.17 2.04 2.11 2.11 441,996
Jan 20, 2026 2.30 2.38 2.17 2.18 2.18 633,604
Jan 16, 2026 2.18 2.38 2.11 2.36 2.36 1,060,705
Jan 15, 2026 2.02 2.31 2.01 2.11 2.11 2,420,751
Jan 14, 2026 1.96 2.00 1.93 1.98 1.98 587,708
Jan 13, 2026 1.96 2.00 1.86 1.97 1.97 551,888
Jan 12, 2026 1.85 2.01 1.82 1.98 1.98 1,174,575
Jan 9, 2026 1.65 1.91 1.65 1.88 1.88 1,304,897
Jan 8, 2026 1.71 1.72 1.61 1.64 1.64 354,433
Jan 7, 2026 1.58 1.73 1.58 1.72 1.72 831,277
Jan 6, 2026 1.54 1.60 1.54 1.55 1.55 261,274
Jan 5, 2026 1.55 1.57 1.51 1.52 1.52 225,074
Jan 2, 2026 1.58 1.59 1.51 1.55 1.55 422,566
Dec 31, 2025 1.46 1.53 1.46 1.53 1.53 313,427
Dec 30, 2025 1.49 1.52 1.43 1.48 1.48 443,096
Dec 29, 2025 1.50 1.53 1.47 1.47 1.47 291,355
Dec 26, 2025 1.54 1.54 1.50 1.54 1.54 143,450
Dec 24, 2025 1.52 1.55 1.51 1.54 1.54 62,847
Dec 23, 2025 1.50 1.54 1.50 1.52 1.52 142,614
Dec 22, 2025 1.50 1.55 1.50 1.53 1.53 336,604
Dec 19, 2025 1.50 1.55 1.50 1.52 1.52 344,836
Dec 18, 2025 1.55 1.59 1.51 1.51 1.51 555,019
Dec 17, 2025 1.67 1.67 1.47 1.52 1.52 2,520,042
Dec 16, 2025 1.49 1.50 1.48 1.49 1.49 250,068
Dec 15, 2025 1.53 1.53 1.48 1.50 1.50 281,567
Dec 12, 2025 1.60 1.60 1.50 1.53 1.53 538,650
Dec 11, 2025 1.62 1.67 1.59 1.60 1.60 149,461
Dec 10, 2025 1.59 1.70 1.59 1.63 1.63 322,445
Dec 9, 2025 1.51 1.72 1.51 1.65 1.65 759,261
Dec 8, 2025 1.53 1.56 1.47 1.55 1.55 287,609
Dec 5, 2025 1.60 1.60 1.50 1.51 1.51 172,693
Dec 4, 2025 1.57 1.61 1.53 1.61 1.61 209,600
Dec 3, 2025 1.51 1.58 1.51 1.57 1.57 114,976
Dec 2, 2025 1.51 1.54 1.48 1.51 1.51 244,833
Dec 1, 2025 1.57 1.57 1.48 1.51 1.51 403,642
Nov 28, 2025 1.57 1.60 1.54 1.56 1.56 132,777
Nov 26, 2025 1.60 1.60 1.56 1.59 1.59 204,955
Nov 25, 2025 1.59 1.62 1.54 1.59 1.59 197,779
Nov 24, 2025 1.56 1.62 1.54 1.59 1.59 353,631
Nov 21, 2025 1.52 1.57 1.51 1.53 1.53 194,312
Nov 20, 2025 1.61 1.66 1.52 1.52 1.52 241,667
Nov 19, 2025 1.61 1.66 1.57 1.60 1.60 308,880
Nov 18, 2025 1.57 1.65 1.56 1.62 1.62 269,160
Nov 17, 2025 1.63 1.68 1.55 1.59 1.59 612,856
Nov 14, 2025 1.60 1.71 1.59 1.64 1.64 195,739
Nov 13, 2025 1.68 1.72 1.62 1.65 1.65 195,949
Nov 12, 2025 1.72 1.73 1.66 1.68 1.68 285,101
Nov 11, 2025 1.67 1.74 1.65 1.72 1.72 182,356
Nov 10, 2025 1.65 1.79 1.62 1.67 1.67 371,035
Nov 7, 2025 1.60 1.63 1.54 1.62 1.62 326,354
Nov 6, 2025 1.62 1.65 1.60 1.64 1.64 197,149
Nov 5, 2025 1.63 1.70 1.62 1.64 1.64 267,777
Nov 4, 2025 1.70 1.74 1.60 1.61 1.61 447,865
Nov 3, 2025 1.78 1.80 1.67 1.73 1.73 427,856
Oct 31, 2025 1.66 1.80 1.61 1.77 1.77 322,789
Oct 30, 2025 1.70 1.71 1.63 1.65 1.65 125,660
Oct 29, 2025 1.70 1.75 1.63 1.65 1.65 360,623
Oct 28, 2025 1.71 1.72 1.66 1.71 1.71 104,377
Oct 27, 2025 1.80 1.81 1.70 1.71 1.71 221,290
Oct 24, 2025 1.74 1.82 1.69 1.80 1.80 333,419
Oct 23, 2025 1.76 1.76 1.64 1.67 1.67 455,534
Oct 22, 2025 1.80 1.80 1.63 1.74 1.74 612,858
Oct 21, 2025 1.83 1.85 1.72 1.76 1.76 388,770
Oct 20, 2025 1.93 2.00 1.82 1.84 1.84 715,640
Oct 17, 2025 2.00 2.00 1.81 1.88 1.88 678,881
Oct 16, 2025 2.03 2.09 1.92 1.95 1.95 808,351
Oct 15, 2025 2.08 2.13 1.99 2.06 2.06 925,647
Oct 14, 2025 2.24 2.25 2.06 2.11 2.11 1,167,952
Oct 13, 2025 1.98 2.38 1.93 2.24 2.24 1,567,842
Oct 10, 2025 1.95 1.99 1.85 1.85 1.85 870,915
Oct 9, 2025 1.80 1.92 1.80 1.92 1.92 383,408
Oct 8, 2025 1.75 1.88 1.75 1.81 1.81 410,334
Oct 7, 2025 1.84 1.84 1.72 1.76 1.76 263,838
Oct 6, 2025 1.76 1.80 1.65 1.79 1.79 421,590
Oct 3, 2025 1.76 1.82 1.62 1.63 1.63 687,776
Oct 2, 2025 1.62 1.81 1.61 1.76 1.76 892,616
Oct 1, 2025 1.46 1.64 1.46 1.60 1.60 761,020
Sep 30, 2025 1.41 1.50 1.40 1.47 1.47 313,430
Sep 29, 2025 1.41 1.45 1.38 1.44 1.44 235,050
Sep 26, 2025 1.40 1.40 1.37 1.38 1.38 88,458
Sep 25, 2025 1.39 1.47 1.37 1.38 1.38 130,956

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Compugen Ltd Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at CGEN, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation